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Abstract
Introduction: Cardiogenic shock (CS) remains the leading cause of death in patients hospitalized for myocardial
infarction (MI). Systemic inflammation with inappropriate vasodilatation is observed in many patients with CS and
may contribute to an excess mortality rate. The purpose of this study was to determine the predictive role of serial
measurements of Nt-proBNP, interleukin-6 (IL-6), and procalcitonin (PCT) for 30-day mortality in patients with CS
due to MI.
Methods: The present study is a prospective single-center study including 87 patients with MI complicated by CS
treated with acute revascularization and intraaortic balloon counterpulsation (IABP) support. Predictive values of
plasma levels at admission (T0), after 24 hours (T1), and after 72 hours (T2) were examined according to 30-day
mortality.
Results: Significant differences between survivors (n = 59) and nonsurvivors (n = 28) were seen for Nt-proBNP at
T0, for IL-6 at T0 and T1, and for PCT at T1 and T2. According to ROC analyses, the highest accuracy predicting
30-day mortality was seen at T0 for IL-6, at T1 for PCT, and at T2 for PCT. In univariate analysis, significant values
were found for Nt-proBNP at T1, and for IL-6 and PCT at all points in time. Within the multivariate analysis, age,
creatinine, and IL-6 were significant determinants of 30-day mortality, in which IL-6 showed the highest level of
significance.
Conclusions: In patients with MI complicated by CS, IL-6 represented a reliable independent early prognostic
marker of 30-day mortality. PCT revealed a significant value at later points in time, whereas Nt-proBNP seemed to
be of lower relevance.
Introduction
Cardiogenic shock (CS) complicating acute myocardial
infarction (AMI) occurs in 5% to 10% of hospitalized
patients and is the leading cause of intrahospital mortality
after AMI [1,2]. Early revascularization of the infarct-
related artery is the fundamental step in therapeutic strate-
gies and has been shown to improve long-term survival in
patients with CS [3,4]. However, some patients fail to show
clinical and hemodynamic improvement, with a poor prog-
nosis despite successful immediate revascularization.
In the classic pathophysiologic view, CS is the result of
temporary and permanent disorders in the circulatory
system [5]. New irreversible injury, reversible ischemia,
and damage from prior infarction contribute to left ven-
tricular dysfunction. N-terminal-pro-B-type natriuretic
peptide (Nt-proBNP) is used for the early diagnosis of
heart failure (HF) in patients with acute dyspnea [6]. In
patients with chronic HF and AMI, Nt-proBNP is a reli-
able predictor of increased mortality [7]. In addition, ele-
vated BNP levels in patients with septic shock are
indicative of septic cardiomyopathy [8].
Systemic inflammation with inappropriate vasodilata-
tion, as evidenced by a normal to low range of systemic
vascular resistance, is observed in many patients with CS
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and may contribute to an excess mortality rate [9].
Accordingly, it has been postulated that CS causes a sys-
temic inflammatory response syndrome (SIRS) by the
release of pro-inflammatory mediators like interleukin-6
(IL-6) and tumor necrosis factor alpha (TNF-a) [5]. Signs
of systemic inflammation such as fever, leukocytosis, and
elevated acute-phase reactants are frequently observed in
patients with AMI and CS. High levels of systemic
inflammation seem to be associated with impaired survi-
val despite early revascularization [5]. It has been shown
that patients with CS and multiorgan failure (MOF) exhi-
bit concentrations of IL-6 of the same magnitude as do
patients with septic shock [10,11].
Procalcitonin (PCT) is a well-established biomarker
for the diagnosis of sepsis [12]. PCT reflects the severity
of bacterial infection and is used to monitor progression
of infection into sepsis, severe sepsis, or septic shock.
Moreover, PCT is used to measure the activity of the
systemic inflammatory response [12]. The increase of
PCT in patients with sepsis correlates with mortality
[12]. A limited number of studies have reported that
increased levels of PCT are related to AMI [13,14].
In the present study, we analyzed the relation between
plasma levels of Nt-proBNP, IL-6, and PCT at different
points in time early after admission and 30-day mortality
in patients with CS due to AMI, treated with immediate
revascularization and IABP support. Moreover, central
determinants of organ failure, hemodynamics, and revas-
cularization were analyzed in relation to short-term prog-
nosis and to levels of Nt-proBNP, IL-6, and PCT.
Materials and methods
Subjects
The present study is a prospective observational single-
center study at a university hospital. Between 2008 and
2010, 87 patients with AMI complicated by CS at admis-
sion were included. The study complies with the Declara-
tion of Helsinki and was approved by the local medical
ethics committee. Patients or, in case of unconsciousness,
relatives signed a consent form. Underlying causes of CS
were categorized as ST-elevation myocardial infarction
(STEMI) and non-ST-elevation myocardial infarction
(NSTEMI). CS was defined by the presence of one of the
following criteria: (a) peak systolic pressure <90 mm Hg
for >30 minutes after the correction of hypovolemia,
hypoxemia, and acidosis or need for vasopressor and/or
inotropic therapy; (b) signs of organ hypoperfusion such as
oliguria/anuria, changes in mental state, or elevated serum
lactate concentrations (>2.0 mM). Patients with ongoing
cardiopulmonary resuscitation (CPR) at admission were
excluded from the study. Further exclusion criteria were
age <18 years, immunosuppressive therapy, preexisting
infectious diseases, mechanical assist devices other than an
intraaortic balloon counterpulsation (IABP), mechanical
cardiac complications, and coronary artery bypass grafting
(CABG) or any surgery in the last 4 weeks before onset of
shock.
All patients were taken directly to the cardiac cathe-
terization laboratory for angiography. All patients had
undergone implantation of an IABP (Datascope System
CS100 and CS100i, Datascope, Oakland, NJ, USA).
Based on the primary outcome variable all-cause mortal-
ity at day 30, analyses were performed to identify differ-
ences between survivors and nonsurvivors and predictors
of worse outcome.
Hemodynamic measurements
Stroke volume (SV) and left ventricular ejection fraction
(EF) were quantified invasively with levocardiography. If
levocardiography could not be performed, EF was quanti-
fied with echocardiography. Cardiac output (CO) (L/min)
was calculated as SV × heart rate. Cardiac power output
(CPO) (W) was calculated as mean arterial pressure
(MAP) × CO/451, left ventricular work (LVW) as (MAP -
left ventricular end-diastolic pressure (LVEDP)) × CO ×
0.0136 (kg-m/min), and systemic vascular resistance (SVR)
(dyne s/cm5) as 80 × (MAP - central venous pressure
(CVP))/CO. Left ventricular work index (LVWI) (kg-m/
min × m²), cardiac power index (CPI) (W/m²), and sys-
temic vascular resistance index (SVRI) (dyne s/cm5/m²)
were computed by substituting CO with CI in the respec-
tive formulas. Stroke work (SW) (g-m) was calculated as
(MAP - LVEDP) × 0.0136 × SV. Stroke work index (SWI)
(g-m/m²) was determined by SW/body surface area.
Microcirculatory power index (micPI) was calculated as
CI × (MAP-CVP) × Hkt-factor.
Blood sampling
The first blood sample (T0) was taken immediately after
admission. The second blood sample (T1) was taken after
24 hours, and the third blood sample (T2), after 72 hours.
Nt-proBNP (Siemens Healthcare Diagnostics GmbH,
Munich, Germany), IL-6 (Siemens Healthcare Diagnostics
GmbH) and PCT (Roche Diagnostics GmbH, Mannheim,
Germany) were measured immediately. Further routine
laboratory parameters were quantified by using commer-
cially available assays.
Organ failure
Acute renal failure was defined as an increase of the
serum creatinine concentration >2.5 mg/dl, an increase
in creatinine >25% from baseline, a diuresis <500 ml/24
hours, or need for hemofiltration. Estimated glomerular
filtration rate (eGFR) was calculated by using the Cock-
roft and Gault formula. Systemic inflammatory response
syndrome (SIRS) was defined by approved criteria [5].
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Multiorgan failure (MOF) was defined as presence of
two or more organ failures, other than cardiovascular.
As scoring system of ICU mortality the APACHE II
score was used.
Statistical analysis
Continuous variables are expressed as mean ± standard
deviation (SD) if normally distributed and as median
(interquartile range) if not normally distributed. Continu-
ous variables were tested for normal distribution with the
use of the Kolmogorov-Smirnov test. The Student t test
was performed for normally distributed continuous vari-
ables, and the Mann-Whitney U test for nonnormally
distributed continuous variables. Testing for homogene-
ity of variance was performed with the Levene test.
Categoric variables are given as frequencies and percen-
tages, and the c2 test with the Fisher Exact test was used
for data analysis. Receiver operating characteristics
(ROC) curves were performed to determine cut-off levels
of Nt-proBNP, IL-6, and PCT, with the highest sensitivity
and specificity predicting 30-day mortality. The cumula-
tive survival plots were estimated with the Kaplan-Meier
method. Survival in groups was compared with the log-
rank test. Univariate Cox regression analysis was per-
formed to identify significant independent predictors of
outcome.
For multivariate analysis, age, CPI, mean dose of cate-
cholamines, lactate, creatinine, and IL-6 or PCT were
included. For this analysis, a backward stepwise selection
method was used. Results are reported as adjusted
hazard ratio (HR) with 95% confidence interval (CI). A
two-sided P value less 0.05 was considered statistically
significant. Statistical analyses were performed by using
SPSS software version 18.0 (SPSS, Chicago, IL, USA).
Results
Primary end point 30-day mortality
The overall 30-day mortality was 32.2% (n = 28 nonsurvi-
vors, n = 59 survivors). No patient died in the catheteriza-
tion laboratory. Six patients died before T1, and six further
patients died before T2. Main cause of death was MOF.
Mortalities showed no significant differences in STEMI
versus NSTEMI patients, male versus female patients, or
patients older than 75 years versus 75 years or younger
(data not shown).
Baseline patient characteristics
Baseline patient characteristics of survivors and nonsur-
vivors are shown in Table 1. Age, percentage of patients
receiving mechanical ventilation, serum lactate levels,
hemoglobin, and serum creatinine differed significantly
between the nonsurvivor and survivor groups. There
were no further differences concerning patient charac-
teristics and demographic data.
Diagnostic and therapeutic characteristics
All patients underwent coronary angiography immedi-
ately after admission. Diagnostic and therapeutic charac-
teristics are summarized in Table 2. Percutaneous
coronary intervention (PCI) was performed technically
successfully in 77 (96.3%) patients, defined by a patent
vessel with TIMI >2 flow, <50% residual stenosis, and
no emergency CABG. Rates of successful PCI were simi-
lar in both groups (Table 2). The most common reasons
for not attempting revascularization/surgery were a
high-risk operation due to low ejection fraction, irrever-
sible MOF, and coronary vessels not suitable for PCI or
CABG. Rate of periinterventional CPR was significantly
elevated in the nonsurvivor group.
Hemodynamic parameters and catecholamine support
Values of hemodynamic measurements at admission are
illustrated in Table 3. For CPI, a significant difference
was observed. In addition, MAP and systolic BP were
reduced within the nonsurvivor group, whereas heart
rate and maximal CVP within the first 24 hours were
elevated in this group. Patients (68; 78.2%) required sup-
portive catecholamine therapy within the first 24 hours,
the more in the nonsurvivor group (Table 3).
Predictive value of Nt-proBNP, IL-6, and PCT for 30-day
mortality
Main purpose of the present study was to determine the
predictive value of serial measurements of Nt-proBNP,
IL-6, and PCT for 30-day mortality. Medians (interquartile
ranges) in all patients accounted for Nt-proBNP, 4,065
(1,147/9,775) pg/ml at T0, 3,588 (1,667/7,376) pg/ml at T1,
and 2,409 (1,082/5,235) pg/ml at T2; IL-6, 74.7 (18.1/255.5)
pg/ml at T0, 46.5 (28.2/136.0) pg/ml at T1, and 26.8 (10.4/
83.4) pg/ml at T2; PCT, 0.25 (0.10/1.40) μg/L at T0, 0.53
(0.10/1.68) μg/L at T1, and 0.43 (0.15/0.90) μg/L at T2. Sig-
nificant differences between survivors and nonsurvivors
were seen for Nt-proBNP at T1 (2,831 versus 6,871 pg/ml;
P = 0.024), for IL-6 at T0 (30.7 versus 424.0 pg/ml; P <
0.0001), and T1 (41.9 versus 79.1 pg/ml; P = 0.015), and for
PCT at T1 (0.46 versus 2.42 μg/L; p = 0.001) and T2 (0.32
versus 1.44 μg/L; P = 0.001) (Figure 1). In contrast, for
CRP, no statistical differences were seen (data not shown).
ROC curves calculated for Nt-proBNP, IL-6, and PCT
at T0, T1, and T2 are illustrated in Figure 2. At the ear-
liest point in time, T0, only IL-6 was predictive of 30-day
mortality; at T1, IL-6 and PCT showed significant
P values, at T2 PCT and Nt-proBNP were predictive of
mortality. Comparing the area under the curve of the
parameters at each point in time, the highest accuracy in
predicting 30-day mortality was seen for IL-6 at T0, for
PCT at T1, and for PCT at T2 (Figure 2). Notably, the
highest level of significance was found for IL-6 at T0.
Based on these analyses, corresponding cut-off levels
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with highest sensitivity and specificity were calculated: T0
IL-6, 307 pg/ml (sensitivity, 57.1%; specificity, 97.7%); T1
PCT, 1.23 μg/L (sensitivity, 83.3%; specificity, 81.4%); T2
PCT, 0.71 μg/L (sensitivity, 90.0%; specificity, 82.9%).
Based on these cut-off levels, 30-day survival rates of
patients according to Kaplan-Meier analyses differed
highly significantly (Figure 3). Survival of patients with
IL-6 levels below the cut-off value was significantly
improved compared with that of patients with IL-6 levels
above the cut-off value, irrespective of the presence of
SIRS (P < 0.05).
Organ failure as predictor of 30-day mortality
Acute kidney injury (AKI) occurred in 31 (35.6%) patients.
AKI appeared significantly more frequent in nonsurvivors
(67.9%) compared with survivors (20.7%; P < 0.0001).
Serum creatinine at admission (1.99 (1.45/3.45) mg/dl ver-
sus 1.34 (1.09/1.58) mg/dl) and eGFR (38.2 ± 19.4 ml/min
versus 67.7 ± 31.5 ml/min) after the first 24 hours also dif-
fered significantly between the groups (P < 0.0001). The
incidence of MOF was increased dramatically in the
nonsurvivor group (60.7% versus 6.8%; P < 0.0001).
According to Kaplan-Meier analyses, the overall 30-day
survival rate of patients with MOF was markedly lower
than that of patients without MOF (15.0% versus 84.8%; P
< 0.0001 by log-rank test). The overall survival rate of
patients with an APACHE II score above the median was
in trend lower than that of patients below this cutoff
(62.9% versus 81.8%; P = 0.065). Initial serum lactate as a
marker for organ hypoperfusion was clearly elevated within
the nonsurvivor group (5.8 (1.6/12.7) mM versus 1.4 (1.1/
3.2) mM; P < 0.01).
Univariate and multivariate analyses of predictors for
30-day mortality
In univariate analysis, significant values were found for
Nt-proBNP at T1, for IL-6 at all points in time, and for
PCT also at all points in time (Table 4). Further signifi-
cant predictors are shown in Table 4. Within the multi-
variate analysis including age, CPI at admission, total
mean dose of catecholamines within first 24 hours, lac-
tate at admission, creatinine at admission, IL-6 at
Table 1 Baseline characteristics of study population according to outcome
All patients(n = 87) Survivors(n = 59) Nonsurvivors(n = 28) P value
Age (years) 67.78 ± 13.4 64.68 ± 14.3 74.32 ± 8.4 <0.0001
Age >75 years (%) 35 (40.2) 19 (32.2) 14 (50.0) 0.156
Male (%) 68 (78.2) 46 (78.0) 22 (78.6) 0.949
STEMI/NSTEMI (%) 44/43 (50.6/49.4) 30/29 (50.8/49.2) 14/14 (50.0/50.0) 0.941
Diabetes (%) 29 (33.3) 21 (35.6) 8 (28.6) 0.629
Hypertension (%) 53 (60.9) 37 (62.7) 16 (57.1) 0.645
Dyslipidemia (%) 43 (49.4) 31 (52.5) 12 (42.9) 0.493
Smoker (%) 31 (35.6) 23 (39.0) 8 (28.6) 0.473
Obesity (%) 20 (23.0) 15 (25.4) 5 (17.9) 0.587
BMI (kg/m2) 27.6 ± 5.5 27.7 ± 5.8 27.2 ± 4.8 0.739
Family history (%) 11 (12.6) 7 (11.9) 4 (14.3) 0.741
CAD (%) 42 (48.3) 28 (47.5) 14 (50.0) 0.825
Previous MI (%) 25 (28.7) 17 (28.8) 8 (28.6) 0.981
Previous PCI (%) 24 (27.6) 17 (28.8) 7 (25.0) 0.801
Previous CABG (%) 6 (6.9) 4 (6.8) 2 (7.1) 0.950
Chronic heart failure (%) 11 (12.6) 8 (13.6) 3 (10.7) 0.978
Previous stroke (%) 10 (11.5) 8 (13.6) 2 (7.1) 0.490
Chronic renal failure (%) 10 (11.5) 5 (8.5) 5 (17.9) 0.281
Mechanical ventilation at admission (%) 43 (49.4) 28 (47.5) 15 (53.6) 0.651
Mechanical ventilation at any time (%) 62 (71.3) 36 (61.0) 26 (91.3) 0.013
Transferred patients (%) 39 (44.8) 29 (49.2) 10 (35.7) 0.259
Preclinical CPR (%) 23 (26.4) 16 (27.1) 7 (25.0) 0.834
Serum creatinine (mg/dl) 1.44 (1.17/2.10) 1.34 (1.09/1.58) 1.99 (1.45/3.45) <0.0001
Hemoglobin (g/dl) 12.5 (10.5/14.4) 13.1 (11.1/14.9) 10.8 (10.0/13.5) 0.034
Troponin I (ng/ml) 14.7 (2.9/62.5) 9.1 (1.9/54.4) 21.0 (9.0/77.0) 0.069
Blood glucose (mg/dl) 199.0 ± 129.9 201.3 ± 142.1 193.3 ± 96.5 0.942
Serum lactate (mM) 1.9 (1.1/6.0) 1.4 (1.1/3.2) 5.8 (1.6/12.7) 0.008
Values are expressed as n (%), or mean ± SD. BMI, body mass index; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CPR, cardiopulmonary
resuscitation; MI, myocardial infarction; NSTEMI, non-ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial
infarction.
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Table 2 Procedural characteristics of study population according to outcome
All patients(n = 87) Survivors(n = 59) Nonsurvivors(n = 28) P value
EF (%) 35.2 ± 11.6 34.7 ± 11.6 36.4 ± 11.9 0.548
EF <30% (%) 24 (27.6) 16 (27.1) 9 (32.1) 0.789
Three-vessel disease (%) 51 (58.6) 34 (57.6) 17 (60.7) 0.814
Infarct artery
Left main (%) 6 (6.9) 4 (6.8) 2 (7.1) 0.950
Left anterior descending (%) 43 (49.4) 29 (49.2) 14 (49.2) 0.941
Right coronary artery (%) 21 (24.1) 13 (22.0) 8 (28.6) 0.691
Left circumflex (%) 24 (27.6) 15 (25.4) 9 (32.1) 0.690
Bypass graft (%) 1 (1.1) 1 (1.7) 0 (0) 0.488
Revascularization procedure (PCI or CABG) (%) 82 (94.3) 57 (96.6) 25 (89.3) 0.323
PCI left main (%) 12 (13.8) 10 (16.9) 2 (7.1) 0.323
PCI success (%) 77 (96.3) 55 (96.5) 22 (95.7) 0.858
CABG (%) 2 (2.3) 0 (0%) 2 (7.1) 0.091
Number of treated vessels 1.26 ± 0.54 1.26 ± 0.48 1.25 ± 0.68 0.932
Time to reperfusion (hours) 6.1 ± 5.2 5.6 ± 4.6 7.3 ± 5.9 0.072
Duration of IABP support (hours) 54.5 ± 24.0 55.4 ± 20.8 52.1 ± 31.3 0.654
TIMI flow before PCI 0.51 ± 0.67 0.51 ± 0.67 0.50 ± 0.71 0.958
TIMI flow after PCI 2.77 ± 0.57 2.82 ± 0.51 2.67 ± 0.70 0.343
CPR periinterventional (%) 12 (13.8) 5 (8.5) 7 (25.0) 0.040
Values are expressed as n (%), or mean ± SD. CABG, coronary artery bypass graft; CPR, cardiopulmonary resuscitation; EF, ejection fraction; IABP, intraaortic
balloon counterpulsation; PCI, percutaneous coronary intervention; TIMI, thrombolysis in myocardial infarction.
Table 3 Hemodynamics and catecholamine support according to outcome
All patients(n = 87) Survivors(n = 59) Nonsurvivors(n = 28) P value
Hemodynamics
CI (L/min/m2) 2.15 ± 0.83 2.16 ± 0.78 2.12 ± 0.93 0.825
CPI (W/m2) 0.35 ± 0.15 0.37 ± 0.15 0.30 ± 0.15 0.041
CPO (W) 0.67 ± 0.26 0.70 ± 0.27 0.60 ± 0.25 0.102
Microcirculatory PI 97.51 ± 46.17 101.74 ± 43.08 86.23 ± 53.22 0.181
SV (ml) 52.6 ± 16.5 54.7 ± 16.8 48.1 ± 15.4 0.078
SVI (ml/m2) 26.8 ± 9.4 28.0 ± 9.0 24.3 ± 9.8 0.105
SW (g m) 37.5 ± 18.5 39.4 ± 18.6 31.7 ± 17.5 0.121
SWI (g m/m2) 19.1 ± 10.2 20.2 ± 10.1 16.0 ± 10.2 0.137
LVW (kg m/min) 2.88 ± 1.35 2.97 ± 1.35 2.60 ± 1.37 0.327
LVWI (kg m/min/m2) 1.47 ± 0.77 1.53 ± 0.74 1.30 ± 0.84 0.320
SVR (dynes sec/cm5) 1,251.8 ± 672.9 1,285.3 ± 705.6 1,146.6 ± 566.9 0.444
SVRI (dynes sec/cm5/m2) 2,281.6 ± 898.2 2,302.9 ± 894.2 2,216.2 ± 938.8 0.756
MAP (mm Hg) 71.1 ± 15.0 74.8 ± 13.7 63.8 ± 14.9 0.002
Min. MAP (mm Hg) day 1 55.1 ± 13.1 58.9 ± 10.9 45.8 ± 13.7 0.001
Systolic BP (mm Hg) 94.8 ± 22.7 98.6 ± 21.7 85.5 ± 23.0 0.036
Min. systolic BP (mm Hg) day 1 70.9 ± 17.7 75.8 ± 15.7 59.0 ± 16.8 0.001
LVEDP (mm Hg) 23.1 ± 8.9 22.9 ± 9.3 23.7 ± 8.1 0.748
CVP (mm Hg) 12.7 ± 5.8 12.2 ± 5.0 13.8 ± 7.6 0.416
Max. CVP (mm Hg) day 1 19.0 ± 8.3 17.2 ± 7.4 23.9 ± 8.9 0.008
HR (beats/min) 82.1 ± 21.2 78.7 ± 19.4 89.4 ± 23.2 0.043
Min. HR (beats/min) day 1 59.0 ± 17.3 56.4 ± 13.7 65.5 ± 23.3 0.115
Max. HR (beats/m) day 1 123.2 ± 25.3 118.8 ± 23.8 134.0 ± 26.2 0.032
Scvo2 (%) 66.3 ± 16.9 67.6 ± 16.5 63.2 ± 18.0 0.378
Min. Scvo2 (%) day 1 56.3 ± 13.5 56.2 ± 12.4 56.7 ± 16.3 0.905
Inotropic and vasopressor support
Catecholamine use (%) 68 (78.2%) 43 (72.9) 25 (89.3) 0.101
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admission, and PCT at admission, age, creatinine, and IL-
6 were significant determinants of 30-day mortality in
which IL-6 showed the highest level of significance
(Table 5).
Discussion
The aim of the present study was to analyze the predictive
value of a broad spectrum of clinical and laboratory para-
meters in patients with CS due to AMI treated with
immediate revascularization. To the best of our knowledge,
this is the first prospective investigation in the early phase
of AMI and CS analyzing serial measurements of Nt-
proBNP, IL-6, and PCT as predictors of 30-day mortality.
Growing evidence indicates that an aggressive strategy
based on immediate coronary revascularization and
IABP support is the most effective therapy for CS due
to AMI [2,5]. Characteristics of our study population
were similar to those of the patients undergoing revas-
cularization in the Should We Emergently Revascularize
Occluded Coronaries for Cardiogenic Shock (SHOCK)
trial [15]. The present study was based on a therapy
strategy that included urgent revascularization and sup-
port by an IABP. In contrast to the SHOCK trial, the
predominant proportion of patients was revascularized
by PCI with a high success rate and revealed a 30-day
mortality of 32%, an incidence lower than that reported
in the SHOCK trial [15].
Nt-proBNP, IL-6, and PCT as predictors of outcome
The measurement of serum levels of natriuretic peptides
is established in the diagnosis and follow-up of chronic
HF. Maisel et al. [6] showed that BNP may be helpful in
Table 3 Hemodynamics and catecholamine support according to outcome (Continued)
Dobutamine use (%) 52 (59.8) 33 (55.9) 20 (71.4) 0.240
Mean dose of dobutamine (µg/min) day 1 500 (0/975) 250 (0/700) 950 (0/1,075) 0.021
Norepinephrine use (%) 64 (73.6) 39 (66.1) 25 (89.3) 0.036
Mean dose of nor-epinephrine (µg/min) day 1 10 (0/61) 3 (0/15) 100 (40/130) <0.0001
Epinephrine use (%) 25 (28.7) 8 (13.6) 18 (64.3) <0.0001
Mean dose of epinephrine (µg/min) day 1 0 (0/0.5) 0 (0/0) 15 (0/80) <0.0001
Total number of catecholamines 2.0 (1.0/2.0) 2.0 (0.0/2.0) 3.0 (2.0/3.0) 0.001
Total mean dose of catecholamines (µg/min) day 1 503 (0.6/1013) 305 (0/706) 995 (165/1310) 0.006
Values are expressed as n (%), mean ± SD, or median with interquartile range (quartile 1 to quartile 3). Beats/min, beats per minute; BP, blood pressure; CI,
cardiac index; CO, cardiac output; CPI, cardiac power index; CPO, cardiac power output; CVP, central venous pressure; HR, heart rate; LVEDP, left ventricular end-
diastolic pressure; LVW, left ventricular work; LVWI, left ventricular work index; MAP, mean arterial pressure; max, maximal; min, minimal; Scvo2, central venous
oxygen saturation; SV, stroke volume; SVI, stroke volume index; SVR, systemic vascular resistance; SVRI, systemic ventricular resistance index; SW, stroke work; SWI,
stroke work index.
Figure 1 Serial measurements of Nt-proBNP (a), interleukin-6 (IL-6) (b) and procalcitonin (PCT) (c) in survivors versus nonsurvivors at
admission (T0), after 24 hours (T1), and after 72 hours (T2). In the box-and-whisker plot, the central box represents the interquartile range
(IQR); the middle line represents the median. Outside values (○) are smaller/larger than the lower/upper quartile ± 1.5 × the IQR; far-out values
(*) are smaller/larger than the lower/upper quartile ± 3 × the IQR.
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diagnosing acute HF in the emergency setting. More-
over, Nt-proBNP has been suggested as a useful marker
of high risk in acute myocardial infarction. Higher base-
line levels of BNP in patients presenting with STEMI
were associated with impairment of reperfusion after
fibrinolytic therapy, whereas patients in the highest
BNP-concentration quartile had an 11-fold risk of dying
by 30 days [16]. Similarly, Nt-proBNP was previously
shown to be predictive of myocardial damage, develop-
ment of CS, and short- and long-term mortality [17,18].
Data concerning the predictive value of serial Nt-
proBNP measurements in patients with manifest CS due
Figure 2 Receiver operating characteristic (ROC) curves for 30-day mortality. Analysis of 30-day mortality calculated from values of Nt-
proBNP, interleukin-6 (IL-6), and procalcitonin (PCT) at admission (T0) (a), after 24 hours (T1) (b), and after 72 hours (T2) (c). ROC curve analysis
with area under the curve and significance levels.
Figure 3 Kaplan-Meier survival curves according to cut-off levels of interleukin-6 (IL-6) (a) and procalcitonin (PCT) (b, c). Estimated 30-
day survival in patients with levels of IL-6 above or below the cut-off level (307 pg/ml) at admission (T0) (a); of PCT (1.23 µg/L) after 24 hours
(T1) (b); of PCT (0.71 µg/L) after 72 hours (T2) (c). P values were estimated by log-rank test.
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to AMI are rare. In the present study, the survivor
group showed a decline of Nt-proBNP levels within 72
hours, whereas in the nonsurvivor group, maximum
levels were reached after 24 hours. Significant differ-
ences of Nt-proBNP were found only after 24 hours
between survivors and nonsurvivors. Notably, Nt-
proBNP revealed no predictive value for the develop-
ment of MOF. In a retrospective study with 58 patients
with CS largely secondary to AMI, initial Nt-proBNP
levels above the median were associated with worsened
outcome [19]. However, Nt-proBNP levels were not ana-
lyzed serially. Next to the retrospective study design, the
number of patients was small in particular if the cohort
was further subdivided. Among the 47 patients who had
AMI as the primary cause of CS, only in 33 patients was
coronary revascularization performed, with a success
rate of 85% [19]. In our study, revascularization was
attempted in 94% of patients, with a success rate of
96%, and an IABP was placed in all patients.
In patients with septic shock, IL-6 levels have been
shown to correlate with disease severity and outcome
[20]. However, elevations are not sepsis specific. It has
been shown that patients with CS and manifest MOF
exhibit similarly high IL-6 levels, as in patients with
Table 4 Univariate analysis predicting 30-day mortality
HR (95% CI) P value
Patient characteristics
Age, per 10 years 1.638 (1.174-2.285) 0.004
EF, per 5% 1.061 (0.887-1.269) 0.516
Left main 2.143 (0.504-9.117) 0.302
STEMI 1.005 (0.479-2.108) 0.989
Mechanical ventilation 1.313 (0.625-2.762) 0.472
Hemodynamics and catecholamines
CO, L/min 0.986 (0.760-1.279) 0.915
CI, L/min/m2 0.934 (0.594-1.468) 0.768
CPI, 0.1 W/m2 0.766 (0.593-0.991) 0.043
CPO, 0.1 W 0.874 (0.747-1.023) 0.094
Microcirculatory PI/10 0.888 (0.795-0.992) 0.036
SVRI, 100 dynes sec/cm5/m2 0.992 (0.937-1.050) 0.776
MAP, 5 mm Hg 0.821 (90.726-0.928) 0.002
Heart rate, 5 beats/min 1.086 (1.003-1.176) 0.041
Catecholamine use 3.073 (0.716-13.198) 0.131
Total number of catecholamines 2.332 (1.350-4.029) 0.002
Mean dose of catecholamines, 10 µg/min 1.014 (1.004-1.024) 0.006
Organ failure
Acute kidney injury 5.084 (2.290-11.290) <0.0001
SIRS 1,412 (0.639-3.121) 0.394
MOF 8.317 (3.754-18.425) <0.0001
Lactate, mM 1.164 (1.086-1.247) <0.0001
APACHE II > Median 2.390 (0.908-6.294) 0.078
Laboratory measurements
Creatinine T0, mg/dl 1.299 (1.092-1.546) 0.003
Creatinine T1, mg/dl 2.155 (1.534-3.028) <0.0001
Creatinine T2, mg/dl 1.562 (0.626-3.901) 0.339
Nt-proBNP T0, 1,000 pg/ml 1.022 (0.988-1.056) 0.204
Nt-proBNP T1, 1,000 pg/ml 1.111 (1.045-1.182) 0.001
Nt-proBNP T2, 1,000 pg/ml 1.109 (0.959-1.282) 0.161
IL-6 T0, 100 pg/ml 1.019 (1.008/1.030) 0.001
IL-6 T1, 100 pg/ml 1.134 (1.023-1.257) 0.016
Il-6 T2, 100 pg/ml 1.550 (1.031-2.331) 0.035
PCT T0, µg/L 1.368 (1.075-1.741) 0.011
PCT T1, µg/L 1.266 (1.122-1.429) <0.0001
PCT T2, µg/L 2.980 (1.687-5.265) <0.0001
IL-6, interleukin-6; MOF, multiorgan failure; Nt-proBNP, N-terminal pro-B-type natriuretic peptide; PCT, procalcitonin; SIRS, systemic inflammatory response
syndrome; other abbreviations as in Tables 1 through 3.
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septic shock [10]. In the setting of AMI, IL-6 was identi-
fied as independent prognostic marker [21]. In the pre-
sent study, IL-6 levels differed significantly between the
survivor and nonsurvivor groups at the early points in
time, in which the values at admission showed an
impressive discrepancy. In accordance with that, univari-
ate analysis confirmed the predictive value of IL-6 for
30-day mortality at the early points in time. IL-6 levels
at admission revealed the highest level of significance
within the ROC analyses. A cut-off level of 307 pg/ml
showed a very clear differentiation between survivors
and nonsurvivors within the Kaplan-Meier curves, asso-
ciated with a very high specificity of 98%. Moreover, in
contrast to Nt-proBNP, IL-6 levels at T0 and T1 were
predictive for occurrence of MOF. Our data confirm the
results of a small retrospective study with only initial
measurements of IL-6 that also showed an independent
predictive value of IL-6 for 30-day mortality [11]. It is
hypothesized that next to ischemic myocardium, whole
body ischemia, endotoxin translocation from the gut,
excessive vasopressor therapy, and noncardiac organ
failure are also contributing factors to IL-6 release [22].
Possibly, IL-6 constitutes not only an innocent bystan-
der of inflammatory activation, but also might be an
aggravating factor because IL-6 determines negative ino-
tropic effects on the myocardium [23].
Several studies have demonstrated that elevated levels of
PCT indicate bacterial infection accompanied by a sys-
temic inflammatory reaction [12]. Nevertheless, PCT ele-
vation has been documented in infection-independent
systemic inflammatory reactions. In recent studies, PCT
levels were found to correlate with the extent of coronary
artery disease and adverse outcome [24]. In a retrospective
study, CS patients showed high PCT concentrations, espe-
cially in the presence of MOF and in the absence of signs
of infection [25]. In a further investigation, PCT values
were significantly higher in CS patients compared with
patients with uncomplicated AMI [26]. The prognostic
relevance of PCT in CS was not evaluated. In our study,
both survivors and nonsurvivors reached maximum levels
of PCT at T1. Significant differences between the two
groups were seen at T1 and T2 and were strongly asso-
ciated with outcome. ROC analysis showed the highest
accuracy of predicting 30-day mortality for PCT at T1 and
T2 with a sensitivity and specificity between 80% and 90%.
Notably, when comparing the area under the curve of Nt-
proBNP, IL-6, and PCT, at all points in time, PCT at T1
showed the highest value.
Hemodynamics and organ failure as predictors of
outcome
Hemodynamic data, including CO and pulmonary wedge
pressure, were shown to be the strongest predictors of
death in the GUSTO CS trial [27]. In a retrospective ana-
lysis from the SHOCK trial registry, CPI was the strongest
predictor of mortality [28]. In our study, hemodynamic
measurements also showed a predictive value of CPI in
the univariate but not multivariate analysis.
Impaired renal function is one of the strongest risk fac-
tors for cardiovascular mortality. In a retrospective analysis
in patients with CS due to AMI, 33% developed an AKI
within 24 hours of shock onset and showed a significantly
higher mortality rate than did patients without AKI [29].
In a recent prospective study of STEMI patients with CS,
AKI occurred in 55% of patients, and the in-hospital mor-
tality rate was significantly higher in patients developing
AKI than in patients without AKI [30]. In our study with
STEMI and also NSTEMI patients, AKI occurred in 36%
of patients during first 72 hours after admission. All mea-
sured parameters of renal insufficiency were clearly asso-
ciated with worse outcome.
Irreversible MOF is the main cause of death in CS. Until
now, only a few studies addressed the issue of MOF in
patients with CS. In a small study, 35% of patients with CS
exhibited MOF at admission categorized by the SOFA
score, and an additional 20% developed MOF later during
the clinical stay [10]. In our study, 24% of patients fulfilled
criteria of MOF with a highly significant difference to the
disadvantage of nonsurvivors.
IL-6 is the strongest independent predictor of 30-day
mortality
As the central finding of our study, multivariate analysis
including age, creatinine, lactate, CPI, mean dose of
catecholamines, and IL-6 or PCT showed independent
predictive values for age, creatinine, and IL-6, in which
IL-6 reached the highest level of significance. Therefore,
IL-6 might be a useful marker to identify very early CS
patients who are at high risk of worse outcome. In con-
trast, the relevance of Nt-proBNP as an early prognostic
marker must be challenged. PCT showed also a highly
significant impact but primarily after the very early
phase of AMI and CS.
Table 5 Multivariate Cox proportional hazard ratios for
30-day mortality
Hazard ratios (95% CI) P value
Age, per 10 years 3.372 (1.548-7.348) 0.002
CPI, 0.1 W/m2 0.790 (0.506-1.231) 0.297
Mean dose of catecholamines,
10 µg/min
1.013 (0.997-1.028) 0.116
Lactate T0, mM 1.007 (0.839-1.209) 0.939
Creatinine T0, mg/dl 1.589 (1.033-2.444) 0.035
IL-6 T0, 100 pg/ml 1.036 (1.017-1.055) <0.0001
PCT T0, µg/L 1.236 (0.843-1.812) 0.277
Abbreviations as in Tables 1 through 4.
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Conclusions
The present study demonstrates that in patients with
AMI and CS treated with immediate revascularization
and IABP, the destination of IL-6 at admission reliably
predicts 30-day mortality. For clinical practice, it is
noticeable that a cut-off level of 307 pg/ml is associated
with a very high specificity but moderate sensitivity. In
contrast, Nt-proBNP seemed to be of lower relevance.
In conclusion, selective measurements of circulating
inflammatory markers allow early prognostic estimation
of patients with CS due to AMI. Potential therapeutic
and prognostic interventions modulating the systemic
inflammatory reaction have to be analyzed in further
studies.
Key messages
• Systemic inflammation is observed in many
patients with cardiogenic shock due to myocardial
infarction.
• Interleukin-6 represents a reliable independent
very early prognostic marker of 30-day mortality
with high specificity.
• Procalcitonin is a very reliable predictor of 30-day
mortality 24 and 72 hours after admission, with high
sensitivity and specificity.
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